HGEN

Lenzilumab

Relapsed or Refractory Diffuse Large B-Cell Lymphoma / RR DLBCL

Phase 1b (Results)

Exp Date

Q4 2020

Amp Volatility Score

Catalyst Info & Data Links

TITLE: Lenzilumab for Relapsed or Refractory Large B-Cell Lymphoma - Phase 1b Results

  • ClinicalTrial.gov (NCT04314843): Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma (ZUMA-19)


WHAT IS THE NEXT CATALYST EVENT?

  • 1. Phase Ib results

  • 2. Phase II interim analysis

  • 3. Six-month efficacy data

  • See slide 8 of the corporate slide deck at this LINK


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • 1. December 2020 (Q4 2020)

  • 2. H1 2021

  • 3. H2 2021


PRIOR DATA

PRESS RELEASES

MECHANISM OF ACTION / RATIONALE

  • A recombinant monoclonal antibody against the cytokine granulocyte macrophage colony-stimulating factor (GM-CSF), with potential immunomodulating activity. Upon administration, lenzilumab binds to and neutralizes GM-CSF. This prevents GM-CSF binding to the GM-CSF receptor, which is a heterodimeric protein expressed on myeloid progenitor cells, and prevents GM-CSF-mediated signaling. This may induce apoptosis in and inhibit proliferation of cancer cells that overproduce GM-CSF. GM-CSF plays a key role in the differentiation and proliferation of monocytes, macrophages and granulocytes; elevated levels of GM-CSF are associated with certain autoimmune diseases, inflammatory diseases, and cancers. (Learn more - Cancer.gov)


Updated by HC

#HGEN, #Lenzilumab, #granulocyte_macrophage_colony-stimulating_factor, #GM-CSF, #ZUMA-19, #B-Cell_Lymphoma, #DLBCL

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

Do failures of IL-6 blockers r...

Do you agree that today's announcement of the failure of #RHHBY's IL-6 blocker #Actemra to treat COVID [https://www.roche.com/media/releases/med-cor-2020-07-29.htm] and the prior failure of #REGN's #K...

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon